In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.
In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, “Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.” This poster compares the recovery rate of patients on natalizumab versus those receiving placebo. “Not only do disease modifying therapies like natalizumab cut down on the number of exacerbations, but they cut down on the severity of the exacerbation and improve the chances of having a better recovery from any given exacerbation,” said Dr Lublin.
Dr Lublin said that an interesting topic addressed at ECTRIMS 2013 was identifying the merits of an escalation therapy approach as opposed to an induction therapy approach to treatment. “The big hope for the future right now is to develop disease-modifying therapies that can affect progressive disease,” concluded Dr Lublin.
Discussing Sexuality, Mental Health With AYA Patients Amid the Hematological Treatment Journey
June 14th 2025Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Hematology in Space: Understanding How Blood Behaves Differently in Orbit
June 14th 2025Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further research is needed as commercial spaceflights are poised to grow in popularity.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More